Antimicrobial Agents and Chemotherapy, September 1998, p. 2319-2325, Vol. 42, No. 9
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
-Lactamases
Microbiologie Moléculaire et
Génie des Protéines,
Received 24 June 1997/Returned for modification 12 October
1997/Accepted 30 June 1998
Class A The production of
Clavulanic acid inactivates group 2a, 2b, and 2be
Wise et al. (32) have shown that the sulfone sulbactam
enhances the activities of penicillin G, ampicillin, and carbenicillin against certain All three inactivators are used clinically in combination with
antibiotics to treat intra-abdominal infections, skin and soft tissue
infections, and upper and lower respiratory tract infections (9,
12, 20). Different combinations of antibiotics and inactivators
are used: ticarcillin with clavulanate, amoxicillin with clavulanate,
piperacillin with tazobactam, and ampicillin with sulbactam. These
combinations are used to treat infections caused by bacteria producing
enzymes in group 2, including Pseudomonas aeruginosa,
Serratia marcescens, E. coli, and others (5,
6, 10, 12, 20, 30).
The model enzyme used in the study described here is PSE-4, a
plasmid-derived In this report we describe the structural and functional features of a
mutant PSE-4 Enzymes and antibiotics.
Polynucleotide kinase was purchased
from Pharmacia Biotech (Baie d'Urfé, Québec,
Canada), and restriction endonuclease BamHI was
purchased from New England Biolabs Ltd. (Mississauga, Ontario, Canada).
The Muta-Gene phagemid in vitro mutagenesis kit was purchased from Bio-Rad Laboratories Ltd. (Mississauga, Ontario, Canada). All
antibiotics except nitrocefin were purchased from Sigma Diagnostic Canada (Mississauga, Ontario, Canada); nitrocefin was purchased from Oxoid (Basingstoke, England). Sulbactam and clavulanic acid were
kindly provided by Pfizer Inc. (Groton, Conn.) and SmithKline Beecham
Laboratories (Bristol, Tenn.), respectively. Tazobactam was a generous
gift from Synphar Laboratories Inc. (Edmonton, Alberta, Canada).
Bacterial strains.
Four strains of E. coli were
used: CJ236 (dut ung thi relA; pCJ105 (Cmr)
[Bio-Rad]), JM101 [F' traD36
lacqD(lacZ)M15
proA+B+/supE thiD(lac-proAB],
DH5 Plasmid isolation and DNA sequencing.
Single-stranded
plasmid DNA was prepared for mutagenesis and DNA sequencing as
described previously (29). Sequencing reactions were done
with the Taq sequencing dye terminator from ABI,
Perkin-Elmer Corp. (Foster City, Calif.) loaded on an Applied
Biosystems 373A system. Plasmid DNA was prepared from E. coli by the alkaline lysis procedure (29).
Oligonucleotides and random replacement mutagenesis.
Mutagenesis and phosphorylation of oligonucleotides were carried out as
described by Bio-Rad by using the Muta-Gene kit and a mutagenesis
method (21). The oligonucleotide primers used for
mutagenesis were synthesized with the Oligo1000 DNA synthesizer (Beckman). Construction of the random library was done as described by
Petrosino and Palzkill (28). The first mutagenesis step used a 40-mer oligonucleotide for the insertion of a unique BamHI
restriction site within the targeted nucleotides and changing of the
blaPSE-4 open reading frame.
![]()
ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
-lactamases are inactivated by the suicide
inactivators sulbactam, clavulanic acid, and tazobactam. An examination of multiple alignments indicated that amino acids 216 to 218 differed among class A enzymes. By random replacement mutagenesis of codons 216 to 218 in PSE-4, a complete library consisting of 40,864 mutants was
created. The library of mutants with mutations at positions 216 to 218 in PSE-4 was screened on carbenicillin and ampicillin with the
inactivator sulbactam; a collection of 14 mutants was selected, and
their bla genes were completely sequenced. Purified wild-type and mutant PSE-4
-lactamases were used to
measure kinetic parameters. One enzyme, V216S:T217A:G218R, was examined
for its peculiar pattern of inhibition. There was an increase in the
Km from 68 µM for the wild type to 271 µM
for the mutant for carbenicillin and 33 to 216 µM for ampicillin.
Relative to the wild-type PSE-4 enzyme, 37- and 30-fold increases in
Ki values were observed for the mutant enzyme
for sulbactam and tazobactam, respectively. The results that were
obtained suggested that positions 216 to 218 are important for
interactions with penicillanic acid sulfone inhibitors. In contrast,
V216 and A217 in the TEM-1 class A
-lactamase do not
tolerate amino acid residue substitutions. However, for the PSE-4
-lactamase, 11 of 14 mutants from the library of mutants with mutations at positions 216 to 218 whose sequences were determined had substitutions at position 216 (G, R, A, S) and position 217 (A, S).
The data showed the importance of residues 216 to 218 in their atomic
interactions with inactivators in the PSE-4
-lactamase structure.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
-lactamases is one of several means by which bacteria
can become resistant to
-lactam antibiotics. These enzymes hydrolyze
the amide bond in the
-lactam ring of antibiotics, leading to a
product that has lost its antibacterial properties (22). A
way to counter this resistance is to use compounds that incapacitate
the
-lactamase and that act in synergy with an
antibiotic (19). These agents are known as suicide
inactivators and include clavulanic acid and the penicillanic acid
sulfones tazobactam and sulbactam (7).
-lactamases, rendering the combination of clavulanic
acid and ticarcillin effective in vitro and in animal models of
infections (2, 6, 11). Tazobactam has been shown to be an
inactivator of many group 2
-lactamases (6).
This suicide inactivator acts irreversibly against both serine-based
-lactamases and metallo-
-lactamases (7). Studies have demonstrated that the combination of
tazobactam and piperacillin has a wide spectrum of activity that
includes gram-positive organisms such as staphylococci, as well as many gram-negative aerobic and anaerobic bacteria (9).
-lactamase-producing bacteria like
Bacteroides fragilis, Staphylococcus aureus, and
Escherichia coli in vitro.
-lactamase from gram-negative bacteria.
It was first found in P. aeruginosa (25). It is a
class A
-lactamase of 271 amino acids, with the mature
protein having a molecular mass of 29,810 Da. The PSE-4
-lactamase has a very high rate of hydrolysis of
carbenicillin and is genetically related to the PSE-1, CARB-3, and
CARB-4 carbenicillinases (3). Analysis of the PSE-4 flanking
DNA region revealed an integration site common to antibiotic resistance
genes inserted into transposons of the Tn21 family
(3).
-lactamase, V216S:T217A:G218R, with
different properties related to inhibition by penicillanic acid
sulfones such as sulbactam and tazobactam as they relate to amino acids 216 to 218 (by the standard numbering system for class A enzymes of
Ambler et al. [1]) in the PSE-4 enzyme. We suggest
that residues 216 to 218 could be crucial amino acids that have atomic interactions with suicide inactivators. This was established by computer-assisted modeling and structural comparisons from a
three-dimensional structure model of PSE-4 constructed for TEM-1
(18), S. aureus PC1 (13, 14), and
Bacillus licheniformis 749/C (23) enzymes.
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
F' [F' endA1 hsdR17
(rk
mk
)
supE44 thi-1 recA1 gyrA (Nal') relA1
D(lacIZYA-argF) U169 deoR (f80dlacD(lacZ) M15)], and
BL21(DE3) [F
ompT hsdSB
(rB
mB
)
gal dcm (DE3; purchased from Novagen, Madison, Wis.)].
Plasmid pMON711 is a recombinant plasmid constructed in the cloning
vector pBGS19+ by inserting a 1.1-kb DNA fragment from
pMON707 containing the blaPSE-4 gene
(3).
xe
/x!. For these
calculations
is equal to np (where n is the
pool size and p is the probability of the least or most
common replacement), and x was the number of times that the
sequence occurs in the pool size. For these calculations, x
is fixed equal to zero, giving the equation P = 1
e
np, which is the probability that the
sequence occurs one or more times in the pool (26). To
construct a library of size n, libraries were plated as
single colonies and pooled for DNA preparation, the mutation efficiency
was evaluated by digestion with BamHI, and 10 randomly
picked colonies for the library were tested for the presence of the
BamHI linker. A complete library of mutants was created from
five small libraries pooled together to generate the complete library
consisting of 40,864 mutants.
Antibiotic susceptibility.
MICs were obtained by a
microdilution method with Mueller-Hinton broth in 96-well microtiter
plates. Selected
-lactamase-producing E. coli DH5
cells were grown to 109 CFU/ml, diluted to
105 CFU/ml, and inoculated with 100 µl of broth; and
serial twofold dilutions were tested with each antibiotic. When
carbenicillin MICs were higher than 10,000 µg/ml, we used
concentrations of carbenicillin that varied from 15,000 to 30,000 µg/ml, with an increment of 1,000 µg/ml for each concentration
tested. Plates were examined after 20 h at 37°C, and the lowest
concentration of antibiotic which inhibited visual growth was estimated
to be the MIC. Quality controls included the standard strain E. coli ATCC 29522, values for which were compared with the values
determined by the National Committee for Clinical Laboratory Standards.
-Lactamase purification.
Strains were grown for 3 h
in Terrific Broth (29) containing 50 µg of kanamycin and
ampicillin per ml, and 1 mM
isopropyl-1-thio-
-D-galactopyranoside was added. The
cultures were incubated overnight at 37°C. Periplasmic proteins
(including
-lactamase protein) were isolated by osmotic shock (24). The crude extract obtained was filtered on PD-10 Sephadex 25 columns (Pharmacia Biotech) and was directly loaded onto an
anion-exchange chromatography Econo-Pac Q cartridge (Bio-Rad). Fractions containing
-lactamases were identified with
nitrocefin and by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE). Selected fractions were concentrated and
buffers were exchanged by ultrafiltration with Centriplus 10 and
Centricon 10 filters (Amicon Canada Ltd. Oakville, Ontario, Canada).
Molecular sieve chromatography was done with HiPrep 26/60 Sephacryl
S-100 (Pharmacia Biotech) and a filtration step with 50 mM sodium
phosphate buffer-0.15 M NaCl (pH 7.0) at a flow rate of 1.3 ml/min.
Chromatography was done on a ConSep LC100 apparatus from Millipore
(Nepean, Ontario, Canada). Fractions were selected as described above,
and enzyme purity was estimated by SDS-PAGE with Coomassie blue and
Sypro orange staining (Bio-Rad); the relative densities of the protein bands were estimated with NIH Image software (version 1.60). Enzymes were stabilized in 50% glycerol and 300 µg of ultrapure bovine serum
albumin per ml and were kept in aliquots at
20°C.
Enzyme kinetics.
Kinetic analyses were done at 30°C in 50 mM sodium phosphate buffer (pH 7.0) for 30 s in a CARY 1 spectrophotometer (Varian). Kinetic parameters were determined for
substrates with the corresponding change in molar extinction
coefficients: for nitrocefin, 485 nm and 14,060 M
1
cm
1; for carbenicillin, 232 nm and 1,190 M
1
cm
1; and for ampicillin, 232 nm and 912 M
1
cm
1. The kinetic parameters Vmax
and Km were determined from the rates of
hydrolysis calculated from the initial linear portion of the curve, by
using a least-squares calculation. The concentrations of the substrates
varied from 15 to 1,000 µM for both wild-type and mutant enzymes. In
a 1-ml reaction volume in a quartz cuvette, the concentration of the
wild type enzyme was 3.20 nM and those for the mutants enzymes varied
from 7.80 to 10.60 nM. All experiments were done in triplicate.
Progressive inhibition determinations. A concentration of 2 µM enzyme (PSE-4 and V216S:T217A:G218R) and various concentrations of inactivators (sulbactam and clavulanate) were incubated together at 25°C in a volume of 50 µl. A control containing enzyme with no inactivator was prepared in 50 mM sodium phosphate buffer (pH 7.0). Samples of 2 µl were withdrawn at regular intervals and were immediately diluted in 1,000 µl containing 500 or 700 µM carbenicillin. Reaction rates were monitored for 5 min in a CARY 1 spectrophotometer (Varian). A value of the percentage of the control activity was obtained by dividing an experimental hydrolysis rate from the linear portion of the curve by the value of the control activity obtained at identical time points. This analysis generated a partition ratio defined as the number of inhibitor molecules required to inactivate one enzyme molecule, which is based upon the inhibitor-enzyme ratio that resulted in >90% enzyme inactivation after 18 h of incubation (7).
Values of kcat and kinact were determined for both clavulanate and tazobactam for both the wild-type PSE-4 and the V216S:T217A:G218R variant enzymes. A kinact value was determined by using different inhibitor-to-enzyme ratios in a reaction volume of 100 to 150 µl at 4°C. Enzyme activity was assayed at different time intervals at between 0 and 6 min by taking 10 µl for the wild-type PSE-4 and 20 µl for the variant diluted in 1,000 µl containing 700 µM carbenicillin. Reaction rates were monitored for 30 s, and hydrolysis rates (V0) from the linear portion of the curve were obtained. A plot of V0 versus time was plotted, and the slope (kobs) of the linear portion was calculated. When plotting a double reciprocal of kobs versus the concentration of the inhibitor, the slope is equal to 1/kinact. By using the partition ratio (kcat/kinact) and kinact, a value of kcat is generated. For tazobactam, inhibitor-to-enzyme ratios were between 0.1 and 2.0 with 258 nM wild-type PSE-4. For the variant enzyme, inhibitor-to-enzyme ratios were between 0.05 and 2.0 with 516 nM enzyme. For clavulanate, inhibitor-to-enzyme ratios of 0.1 to 5.0 with 258 nM enzyme were used for both the wild-type PSE-4 and the V216S:T217A:G218R variant enzymes.| |
RESULTS |
|---|
|
|
|---|
Selection of mutants from the library of mutants with mutations at position 216 to 218. Since the library was constructed to study interactions with suicide inactivators, mutants were selected on separate TSA plates containing ampicillin and sulbactam (78 and 8 µg/ml, respectively) and carbenicillin and sulbactam (1,250 and 8 µg/ml, respectively). These concentrations allowed the growth of E. coli producing wild-type PSE-4. To facilitate isolation of enzyme variants expressed in E. coli, selection was done with two- and fourfold the concentrations of substrates while maintaining a constant inhibitor concentration. No mutants were obtained at higher concentrations. However, only 16% of the library was recovered as bacterial colonies on plates with carbenicillin and sulbactam, and only 57% of the library was recovered on plates with ampicillin and sulbactam at concentrations similar to those that allowed the recovery of the wild type. The rest of the library could have comprised unstable or inactive mutants, and mutants were not selected for on this kind of selection medium.
Palzkill and Botstein (27) suggested that the ability to introduce amino acid substitutions in a target protein is central to protein structure and function studies. The tolerance of specific positions to amino acid substitutions defines the importance of the position for the structure and function of the protein. Positions that cannot tolerate substitutions are inferred to be essential for structure and/or function (27). DNA sequencing of the blaPSE-4 gene from the mutants showed gene integrity except at the mutagenesis position generating functional mutants with mutations at positions 216 to 218. As shown in Table 1, a variety of mutants had single, double, or triple amino acid changes. Of 14 variants sequenced, 11 had substitutions at position 216 (G, S, A, R), 11 had substitutions at position 217 (A, S), and 8 had substitutions at position 218 (R, S, A, Q, H). Multiple substitutions were seen in 10 variants. Two had substitutions at positions 216 and 217, one had substitutions at positions 216 and 218, one had substitutions at positions 217 and 218, and six had substitutions at all three positions (Table 1). Although there is variability in the mutants, for some variants such as pMON77020, pMON77022, pMON77023, pMON77024, pMON77025, pMON770228, and pMON77031, interesting patterns in the MICs of substrates or inactivators due to the mentioned substitutions were found, and these could have affected the structure and/or function of the enzyme (Tables 1 and 2).
|
|
Antibiotic and inhibitor susceptibilities. The MICs of ampicillin and carbenicillin were different for the PSE-4 variants that were recovered. Some variants were more susceptible to ampicillin, as seen for variants with V216G:T217A and V216S:T217A:G218R substitutions, in which there were eight- and fourfold increases in susceptibility, respectively (Table 1). When carbenicillin was used, the V216G:T217A variant also had an eightfold increase in susceptibility, some variants had fourfold increases in susceptibility, while for others no significant changes in the MICs were found (Table 1). We noted that all no significant changes in the MICs of piperacillin were found for mutants with mutant enzymes (Table 1). Some variants showed eightfold increases in susceptibility to ticarcillin compared to that of the wild type, but the greatest difference was observed for the V216G:T217A variant, for which the MIC decreased 16-fold (Table 1).
The MICs of three suicide inactivators, sulbactam, tazobactam, and clavulanic acid in combination with ampicillin and carbenicillin as substrates, were determined. For tazobactam with ampicillin or carbenicillin, some mutants showed increased susceptibility compared to that of the wild type. While the MICs of carbenicillin and ampicillin combined with tazobactam for strains carrying the wild-type PSE-4 were 1,000 and 500 µg/ml, respectively, the MICs of both substrates with tazobactam for the mutants decreased two- or fourfold (Table 2). The susceptibilities of the E. coli DH5
variants to
clavulanic acid with ampicillin were not significantly different;
some mutants had a twofold difference, which represents
experimental error. Only for the V216R variant was there a
fourfold decrease in the MIC. For clavulanic acid with
carbenicillin, an eightfold increase in susceptibility
occurred in variants pMON77020, pMON77022, pMON77023, pMON77025,
pMON77028, and pMON77031 (Table 2).
For most of the mutants no more than a twofold decrease in the
MICs of sulbactam with carbenicillin compared to the MICs for the
wild type (2,500 µg/ml) were found. For two variants,
V216G:T217A and V216G:T217S:G218R, however, the MICs were 625 µg/ml
(Table 2). The only significant changes in the MICs of sulbactam with ampicillin was a fourfold decrease in susceptibility from 156 µg/ml
for the wild-type to 625 µg/ml for the V216S:T217A:G218R variant
(Table 2).
Kinetic analysis.
From among the 14 variant enzymes whose
sequences were determined, 1 enzyme was purified to study the effects
of these mutations on catalytic activity. This mutant was chosen
because of the observed pattern in the MICs of suicide
inactivators. The mutant showed a slight decrease in
susceptibility to sulbactam in combination with ampicillin but
increased susceptibility to clavulanic acid in combination with
carbenicillin. Therefore, kinetic parameters for all three
suicide inactivators were determined by using carbenicillin as
the substrate because PSE-4 is classified as a
carbenicillin-hydrolyzing enzyme (6). The
V216S:T217A:G218R
-lactamase from pMON77031 was
purified to a level of purity evaluated by SDS-PAGE to be
99%, as
shown in Fig. 1, lane 3. Kinetic
parameters for ampicillin and carbenicillin hydrolysis were also
determined.
|
|
|
Progressive inhibition determinations.
The activities of the
suicide inactivators were estimated by determining the progressive
inhibition of the enzyme. For clavulanic acid the ratio for turnover
number before inactivation gave an inhibitor-to-enzyme ratio of
80 for both wild-type PSE-4 and the V216S:T217A:G218R
variant. For tazobactam, a partition ratio of 1,000 was found for the
wild-type enzyme, while that for the variant was 250, a fourfold
difference (Table 5). This decrease in
the partition ratio was due to a fivefold reduction in the
kcat value of the V216S:T217A:G218R variant
(Table 5). However, no significant change was seen in clavulanate, for
which the kcat of the wild-type PSE-4 was 72 s
1 while the kcat of the variant
was 58 s
1 (Table 5). We observed no significant
difference in the kinact values of the wild-type
and variant enzymes for both inactivators (Table 5).
|
| |
DISCUSSION |
|---|
|
|
|---|
From the random replacement mutagenesis done at residues 216 to
218 in the PSE-4
-lactamase, we report on a mutant with
a decreased affinity for the suicide inactivators sulbactam and tazobactam. This mutant exhibited substitutions at all three
positions, V216S, T217A, and G218R.
Recent studies have shown that for the TEM-1 class A
-lactamase, V216 and A217 do not tolerate amino acid
residue substitutions (15). For the PSE-4
-lactamase, this is not the case because of the 14 mutants from the library of mutants with mutations at positions 216 to
218 whose sequences were determined, 11 had substitutions at
positions 216 (G, R, A, S) and 217 (A, S). An examination of these residues in the three-dimensional structures of the TEM-1 (18), B. licheniformis 749/C
(23), and S. aureus PC1 (13, 14)
enzymes indicated that the environment around several of these
residues differed among the class A enzymes (15).
In the structure of the TEM-1 enzyme, the V216 side chain is 31% solvent exposed and points into the active site toward the catalytic S70 domain (18). It is suggested that because amino acid residue substitutions are not tolerated at this position, there could be an important role for V216 in ampicillin hydrolysis (15). This leads to an interesting point because for PSE-4 mutant V216S:T217A:G218:R, there was a sixfold increase in the Km for ampicillin and a 10-fold decrease in catalytic efficiency. This suggested that although V216 in the PSE-4 mutant tolerated amino acid substitutions, it could have a role similar to that of TEM-1 in the hydrolysis of ampicillin.
Susceptibility studies confirmed that mutant V216S:T217A:G218:R exhibited a slight decrease in susceptibility to sulbactam with ampicillin and an increase in susceptibility to clavulanic acid with carbenicillin, while no significant changes in susceptibility to tazobactam with both substrates were observed. From the kinetic studies, 37- and 30-fold increases in Ki values relative to those for the wild-type PSE-4 were shown for sulbactam and tazobactam, respectively. No significant difference was found in the Ki value for clavulanic acid. It is interesting that the mutant exhibited a slightly lower level of susceptibility to sulbactam than to tazobactam. This could be explained by the fact that this mutant was selected on medium containing sulbactam.
We compared the MICs and Ki values of the
three inactivators. We observed that clavulanate is more potent
against E. coli containing PSE-4
-lactamase. Although tazobactam showed the highest affinity to the active site of the enzyme compared to the affinities of
the other inactivators, clavulanate had the largest effect on MICs. The
MIC of sulbactam with carbenicillin for the strain producing wild-type
PSE-4 decreased 8-fold, and the MIC of tazobactam for the same strain
decreased 20-fold. However, the MIC of clavulanate decreased 40-fold
compared to the MICs without any inactivators. For the strain producing
the parent PSE-4, the MICs of ampicillin with sulbactam, tazobactam,
and clavulanate decreased 32-, 10-, and 312-fold, respectively.
Clavulanate had the largest effect on the MIC for the strain with
V216S:T217A:G218R, with 320- and 625-fold decreases with carbenicillin
and ampicillin, respectively (Tables 1 and 2). This suggested that
although clavulanate does not have the highest affinity to the enzyme,
the inhibitory effect of clavulanate toward the PSE-4 wild-type and
V216S:T217A:G218R enzymes is more efficient than those of the other
inactivators.
The interaction of clavulanic acid with residues 216 to 218 is very
different from those of sulbactam and tazobactam, or, rather,
clavulanic acid has no interactions with these residues in the PSE-4
enzyme. These results were consistent with those reported by Imtiaz et
al. (17), whose proposed mechanism of inhibition by the
penicillanic acid sulfones was different from that for clavulanic acid.
It was demonstrated that protonation by the conserved crystallographic
water for sulbactam is not thought to be required for the formation of
the inactivating species as it is for clavulanic acid (17).
In addition, the nature of the leaving group at C-5 is very different
between sulbactam and clavulanic acid, explaining the differences in
the mechanisms of inactivation (4). It has also been shown
that R244 plays an important role during the inactivation reaction by
both clavulanate and sulbactam (16, 17). However, the
mechanisms of action and the interactions of these compounds with
the TEM-1
-lactamase were shown to be different
(16, 17).
From the three-dimensional model constructed for PSE-4 by using atomic
coordinates from crystallized TEM-1 (18), S. aureus PC1 (13, 14), and B. licheniformis 749/C (23) enzymes, we observed that
amino acids 216 to 218 were present on a random coil between the
all-
domain and the
/
domain. Although the PSE-4 enzyme has
not yet been crystallized, Strynadka et al. (31) state that the active-site regions of the crystallized TEM-1, PC1, and
B. licheniformis enzymes have very similar conformations, so
that mechanistic deductions based on the structure of TEM-1 are
applicable to other class A enzymes. Therefore, we refer to the
mechanistic results obtained for TEM-1 and apply them to the PSE-4
enzyme. It should be noted that TEM-1 and PSE-4 have 41% amino acid
sequence identity.
The purified PSE-4 mutant enzyme from pMON77031 had an important
change at position 218, where a G residue, a small polar uncharged amino acid, has been substituted for an R residue, a large
positively charged amino acid. Residues 216 to 218 are found at the
interface of the two domains of the enzyme, and the active site lies
between these two domains. A substitution at position 218 from a G to
an R could increase the stability of the enzyme by making a favorable
electrostatic interaction with E273 found at the beginning of the
-11 helix of the
/
domain of the enzyme.
The Ki values obtained indicated increases in
Ki values for sulbactam and tazobactam of 37- and 30-fold, respectively, but no changes in the
Ki value for clavulanate. This difference in the
dissociation constant suggests that the enzyme has less affinity for
the sulfone inactivators sulbactam and tazobactam, while the mutations at positions 216 to 218 did not affect clavulanate
binding. However, while no significant changes in the
kcat and kinact values for clavulanate were observed between wild-type PSE-4 and variant enzymes, a significant decrease in the kcat for
tazobactam was observed for the variant V216S:T217A:G218S enzyme
compared to that for the wild-type PSE-4 enzyme. This suggests that
other than having a role in tazobactam binding, amino acids 216 to 218 are also implicated in the inactivation chemistry. On the other hand
positions 216 to 218 are not implicated in either the binding of
clavulanate or inactivation chemistry in the PSE-4
-lactamase, as seen from the kinetic characteristics for
this inactivator.
For the TEM-1
-lactamase, in the preacylation complex
the hydroxyl group of S235 forms a strong hydrogen bond with the
carboxylate of clavulanate. This carboxylate also forms hydrogen bonds
with invariant residues S130, R244, and crystallographic water W673, so
that a total of four hydrogen bonds exist around the carboxyl anion
(16). In the preacylation complex of TEM-1 with sulbactam, Imtiaz et al. (17) have demonstrated that there is a strong electrostatic attraction for the carboxylate of sulbactam with K234,
S235, and R244. Therefore, there are only three hydrogen bonds in the
preacylation complex with sulbactam, but four are suggested for
clavulanate. This means that the latter has a stronger interaction
in the active site than the former.
Therefore, the interactions between residues in the active site and the suicide inactivators are different for sulbactam, tazobactam, and clavulanic acid. In the V216S:T217A:G218R variant, the mutations in this case affected only residues implicated with sulbactam and tazobactam but not with clavulanate, as seen from the kinetic study results. Imtiaz et al. (16) have demonstrated that in TEM-1 the C-2 substituent of clavulanate lies near the guanidinium moiety of R244. A water molecule, W673, links R244, the clavulanate carboxyl group, and the main-chain carbonyl group of residue 216. In our case a change from V to S at position 216 did not appear to affect the hydrogen bonding between W673 and V216 with the clavulanate carboxyl group. However, other mutations might hinder the accessibility of the main-chain carbonyl group of residue 216 and affect inactivation by clavulanate.
One possible role of residues 216 to 218 is to maintain a kinetically
favorable environment around the active site. A substitution at these positions could affect electrostatic interactions with substrates and with suicide inactivators, inducing changes to the
enzyme's properties as demonstrated in these studies. Further structural studies based on the crystal structure of PSE-4
-lactamase are eventually required to confirm these
results and will help us understand the mechanisms of
-lactamase inactivation.
| |
ACKNOWLEDGMENTS |
|---|
We express our gratitude to Lindsay Eltis for suggestions and comments in the kinetics analysis and in using the Leonora software.
R.C.L. is a Scholar of Exceptional Merit from the Fonds de la Recherche en Santé du Québec. Work in R.C.L.'s laboratory is funded by the Medical Research Council of Canada and by the Centers of Excellence via the Canadian Bacterial Diseases Network.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Microbiologie Moléculaire et Génie des Protéines, Science de la Vie et de la Santé, Faculté de Médecine, Pavillon Charles-Eugène Marchand, Université Laval, Ste-Foy, Québec, Canada G1K 7P4. Phone: (418) 656-3070. Fax: (418) 656-7176. E-mail: rclevesq{at}rsvs.ulaval.ca.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Ambler, R. P.,
F. W. Coulson,
J.-M. Frère,
J.-M. Ghuysen,
B. Joris,
M. Forsman,
R. C. Levesque,
G. Tiraby, and S. G. Waley.
1991.
A standard numbering scheme for the class A -lactamases.
Biochem. J.
276:269-272.
|
| 2. | Barry, A. L., L. W. Ayers, T. L. Gaven, E. N. Gerlach, and R. N. Jones. 1984. In vitro activity of ticarcillin plus clavulanic acid against bacteria isolated in three centers. Eur. J. Clin. Microbiol. 3:203-206[Medline]. |
| 3. |
Boissinot, M., and R. C. Levesque.
1990.
Nucleotide sequence of the PSE-4 carbenicillinase gene and correlations with the Staphylococcus aureus PC1 -lactamase crystal structure.
J. Biol. Chem.
265:1225-1230 |
| 4. |
Bonomo, R. A.,
C. G. Dawes,
J. R. Knox, and D. M. Shlaes.
1995.
-Lactamase mutations far from the active site influence inhibitor binding.
Biochem. Biophys. Acta
1247:121-125[Medline].
|
| 5. |
Brismar, B.,
A. S. Malmborg,
G. Tunevall,
B. Wretlind,
L. Bergman,
L. O. Mentzing,
P. O. Nystrom,
E. Kihlstrom,
B. Backstrand,
T. Skau,
B. Kasholm-Tengve,
L. Sjöberg,
B. Olsson-Liljequist,
F. P. Tally,
L. Gatenbeck,
A. E. Eklund, and C. E. Nord.
1992.
Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections.
Antimicrob. Agents Chemother.
36:2766-2773 |
| 6. |
Bush, K.,
G. A. Jacoby, and A. A. Medeiros.
1995.
A functional classification scheme for -lactamase and its correlation with molecular structure.
Antimicrob. Agents Chemother.
39:1211-1233[Medline].
|
| 7. |
Bush, K.,
C. Macalintal,
B. A. Rasmussen,
V. J. Lee, and Y. Yang.
1993.
Kinetic interactions of tazobactam with -lactamases from all major structural classes.
Antimicrob. Agents Chemother.
37:851-858 |
| 8. | Cornish-Bowden, A. 1995. Analysis of kinetic data. Oxford Science Publications, New York, N.Y. |
| 9. |
Daniel, K. P., and L. C. Krop.
1996.
Piperacillin-tazobactam: a new -lactam- -lactamase inhibitor combination.
Pharmacotherapy
16:149-162[Medline].
|
| 10. | Fink, M. P., C. M. Helsmoortel, E. J. Arous, G. V. Doem, K. P. Moriarty, P. G. Fairchild, and P. L. Townsed. 1989. Comparison of the safety and efficacy of parenteral ticarcillin/clavulanate and clindamycin/gentamicin in serious intra-abdominal infections. J. Antimicrob. Agents 24:147-156. |
| 11. |
Fuchs, P. C.,
A. L. Barry,
C. Thornsberry, and R. N. Jones.
1984.
In vitro activity of ticarcillin plus clavulanic acid against 622 clinical isolates.
Antimicrob. Agents Chemother.
25:392-394 |
| 12. | Hart, S. M., and E. M. Bailey. 1996. A practical look at the clinical usefulness of the beta-lactam/beta-lactamase inhibitor combinations. Ann. Pharmacother. 30:1130-1140[Abstract]. |
| 13. |
Herzberg, O.
1991.
Refined crystal structure of -lactamase from Staphylococcus aureus PC1 at 2.0 Å resolution.
J. Mol. Biol.
217:701-720[Medline].
|
| 14. |
Herzberg, O., and J. Moult.
1987.
Bacterial resistance of -lactam antibiotics: crystal structure of -lactamase from Staphylococcus aureus PC1 at 2.5 Å resolution.
Science
236:694-701 |
| 15. |
Huang, W.,
J. Petrosino,
M. Hirsch,
P. S. Shenkin, and T. Palzkill.
1996.
Amino acid sequence determinants of -lactamase structure and activity.
J. Mol. Biol.
258:688-703[Medline].
|
| 16. |
Imtiaz, U.,
E. Billings,
J. R. Knox,
E. K. Manavathu,
S. A. Lerner, and S. Mobashery.
1993.
Inactivation of class A -lactamase by clavulanic acid: the role of arginine-244 in a proposed nonconcerted sequence of events.
J. Am. Chem. Soc.
115:4435-4441.
|
| 17. |
Imtiaz, U.,
E. M. Billings,
J. R. Knox, and S. Mobashery.
1994.
A structure-based analysis of the inhibition of class A -lactamases by sulbactam.
Biochemistry
33:5728-5738[Medline].
|
| 18. |
Jelsch, C.,
L. Mourey,
J.-M. Masson, and J.-P. Samama.
1993.
Crystal structure of Escherichia coli TEM-1 -lactamase at 1.8 Å resolution.
Proteins Struct. Funct. Genet.
16:364-383.
[Medline] |
| 19. |
Knowles, J. R.
1985.
Penicillin resistance: the chemistry of -lactamase inhibition.
Acc. Chem. Res.
18:97-104.
|
| 20. | Kunkel, T. A., J. D. Roberts, and R. A. Zakour. 1987. Rapid and efficient site-specific mutagenesis without phenotypic selection. Methods Enzymol. 154:367-382[Medline]. |
| 21. |
Lode, H. M.
1996.
Clinical indications for -lactamase inhibitors in comparison to other antibiotics.
Int. J. Antimicrob. Agents
7:S3-S7.
|
| 22. |
Medeiros, A. A.
1984.
-Lactamases.
Br. Med. Bull.
40:18-27 |
| 23. |
Moews, P. C.,
J. R. Knox,
O. Dideberg,
P. Charlier, and J.-M. Frère.
1990.
-Lactamase of Bacillus licheniformis 749/C at 2 Å resolution.
Proteins
7:156-171[Medline].
|
| 24. |
Neu, H. C., and L. A. Heppel.
1965.
The release of enzymes from Escherichia coli by osmotic shock during the formation of spheroplasts.
J. Biol. Chem.
240:3685-3692 |
| 25. | Newsom, S. W. B. 1969. Carbenicillin-resistant Pseudomonas. Lancet ii:1140. |
| 26. |
Palzkill, T., and D. Botstein.
1992.
Probing -lactamase structure and function using random replacement mutagenesis.
Proteins
14:29-44[Medline].
|
| 27. | Palzkill, T., and D. Botstein. 1991. Extracting information from protein sequences using random replacement mutagenesis. Methods 3:155-164. |
| 28. |
Petrosino, J. F., and T. Palzkill.
1996.
Systematic mutagenesis of the active-site omega-loop of TEM-1 -lactamase.
J. Bacteriol.
178:1821-1828 |
| 29. | Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. |
| 30. |
Shlaes, M. D.,
R. Baughman,
C. T. Boylen,
J. C. Chan,
N. B. Charan, and C. Norden.
1994.
Piperacillin/tazobactam compared with ticarcillin/clavulanate in community-acquired bacterial lower respiratory tract infection.
J. Antimicrob. Chemother.
34:565-577 |
| 31. |
Strynadka, N. C. J.,
H. Adachi,
S. E. Jensen,
K. Johns,
A. Sielecki,
C. Betzel,
K. Sutoh, and M. N. G. James.
1992.
Molecular structure of the acyl-enzyme intermediate in -lactam hydrolysis at 1.7 Å resolution.
Nature
359:700-705[Medline].
|
| 32. |
Wise, R.,
J. M. Andrews, and K. A. Bedford.
1980.
Clavulanic acid and CP-45,899: a comparison of their in vitro activity in combination with penicillins.
J. Antimicrob. Chemother.
6:197-206 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |